| scholarly article | Q13442814 |
| P50 | author | Adam S Kibel | Q101212255 |
| P2093 | author name string | H Jeffrey Lawrence | |
| Judd W Moul | |||
| Phillip G Febbo | |||
| Steven E Canfield | |||
| Michael J Kemeter | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy | Q28534277 | ||
| Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies | Q33557377 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients | Q33996270 | ||
| Critical review of prostate cancer predictive tools | Q34104562 | ||
| Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. | Q34962331 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial. | Q35107524 | ||
| Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort | Q35832300 | ||
| Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent | Q36078909 | ||
| Publication of tumor marker research results: the necessity for complete and transparent reporting | Q36417739 | ||
| The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. | Q36615770 | ||
| Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group | Q37038406 | ||
| The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group | Q37277889 | ||
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review | Q38024305 | ||
| Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers | Q40923195 | ||
| Pathological outcomes of candidates for active surveillance of prostate cancer | Q46511086 | ||
| A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. | Q46658469 | ||
| Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. | Q54324284 | ||
| Natural History of Early, Localized Prostate Cancer | Q57199844 | ||
| Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer | Q80226703 | ||
| Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy | Q84811720 | ||
| Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry | Q87371464 | ||
| P433 | issue | 4 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 172-180 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Reviews in urology | Q26853801 |
| P1476 | title | A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer | |
| P478 | volume | 16 |
| Q50074531 | Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer |
| Q33914221 | Emerging proteomics biomarkers and prostate cancer burden in Africa. |
| Q50260314 | Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy |
| Q89105668 | Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study |
| Q38904571 | Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels |
| Q92256981 | Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning |
| Q57117462 | Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment |
| Q52645860 | Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. |
| Q26785506 | The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review |
Search more.